A new drug could improve dermatitis after a single dose

By Maria Cohut, Ph.D.: For More Info, Go Here…

Atopic dermatitis is a common form of eczema that affects millions of people in the United States. Now, a new proof-of-concept study suggests that a novel drug could relieve symptoms after just one dose.

Atopic dermatitis is a common form of eczema that affects millions of people in the United States. Now, a new proof-of-concept study suggests that a novel drug could relieve symptoms after just one dose.

person scratching their arm
A new treatment for atopic dermatitis shows promise in proof-of-concept trial.

Researchers estimate that about 16.5 million adults in the United States have atopic dermatitis.

This is a chronic condition that causes skin to become sore, dry, cracked, and irritated.

There is currently no cure for this skin condition, but doctors can help people find a treatment plan that helps reduce the severity of symptoms when they occur.

Such treatment plans include adjusting diet and lifestyle, using topical creams, and taking other forms of medication, such as immunosuppressants.

Immunosuppressants — which doctors often prescribe to people with severe forms of this condition — include ciclosporin and methotrexate, which work by dampening the body’s immune response to allergens that trigger symptoms of atopic dermatitis.

However, these medications can have side effects, including high blood pressure, liver problems, headaches, dizziness, and nausea.

Researchers are therefore on the lookout for alternative drugs that could also efficiently improve the symptoms of atopic dermatitis.

A new proof-of-concept study — led by researchers from the University of Oxford in the United Kingdom — suggests that a new drug, called “etokimab,” could be an effective alternative.

Significant symptom improvements

For their new study, the researchers recruited 12 participants with atopic dermatitis. Their findings appear in the journal Science Translational Medicine, and the researchers thank AnaptysBio, a clinical stage antibody development company, for funding the small trial.

All participants received a dose of etokimab. This drug targets a signaling molecule called interleukin 33 (IL-33), which has a role in targeting immune responses.

After 29 days, 83% of those who received the treatment displayed significant improvements in physical symptoms of dermatitis, reducing their scores of disease severity by at least half.

At the end of the study period, the participants also showed a 40% reduction in the levels of a particular type of immune cell in the bloodstream. This cell is called eosinophil, and it is linked to how sensitive a person is to different allergens.

“This clinical trial is the first time we’ve looked at how blocking IL-33 can help [people] with atopic dermatitis, and we have found they experienced significant improvement in their symptoms after a single dose,” says lead researcher Prof. Graham Ogg.

Leave a Reply